In dogs islet culture plus a single injection of anti-lymphocyte serum induced increased survival of allogeneic islets. The yield of islets from human pancreas remains unsatisfactory.
Dr. D. Lorenz (Berlin) described further developments of his techniques for isolation of human islets. Further reports concentrated on the use of cyclosporin A and its immunosuppressive effect in clinical and experimental pancreas transplantation. At present, it is controversial as to whether cyclosporin A influences insulin secretion. Furthermore, several discussants stressed the point that cyclosporin A should not be given together with anti-lymphocytic globulin because of the risk of white cell dyscrasias.
Dr. J. Dupre and Dr. C. R. Stiller (Ontario) reported on their first experience of cyclosporin A in the treatment of 41 patients with recent onset Type 1 (insulin-dependent) diabetes. Patients treated within 6weeks from diagnosis had better results than those treated 6-44weeks after diagnosis of diabetes. Of 30patients in the former group, 16 showed remission, i.e. no concomitant insulin treatment was needed. The cyclosporin A dose was 10 mg/kg body weight to start with and then serum levels were maintained at 120-130 ng/ml. Some patients showed mild anaemia of unknown origin and 30% developed gingivae-hyperplasia. Treatment was continued for 1 year.
During the second part of the Workshop, intensified insulin therapy and insulin pumps were discussed. Some groups reported on the application of microcomputers for the calculation of insulin doses. Calculations were performed on the basis of the actual blood glucose concentration, taking glucose control and insulin dosage during preceding days into account. Dr. A.M.Albisser (Toronto) presented a commercially available pocket computer programmed for this purpose.
New insulin pumps were introduced in an exhibition and in communications. These pumps are smaller than previous ones, have greater programming facilities, improved electronics and more alarm functions. In the field of implantable pumps, two new models (Medtronic and Pacesetter) will soon be available for use in human beings. Besides these technical reports there were communications on the stability of pump insulins. It is evident that absolutely stable insulins are not yet available. Moreover, stability depends on the syringe and catheter materials used. Dr. S.G. Melberg (Bagsvaerd, Denmark) reported on changes in insulin solutions after contact with different infusion catheters. Apparently, selection of materials in contact with insulin is not only important in implantable but also in externally worn pumps.
There were several communications on the effects of normalization of blood glucose control on hormone and metabolite concentrations. Although an amelioration of these disturbances was found in most experiments, complete normalization has not been observed under all circumstances. Furthermore, reports of the superiority of portal compared with peripheral insulin delivery were discrepant. The in-fluence of tight blood glucose control on the late complications of diabetes was reported by four groups in respect of neuropathy. Improvements in pain, motor nerve conduction velocity and autonomic neuropathy were observed in many patients. Reports of changes in sensory nerve conduction velocity were contradictory. This could be due to methodological problems.
Analysis of the European survey of treatment with external insulin pumps was presented by W. Kerner (Ulm). The most notable observation was high incidence of ketoacidosis and severe hypoglycaemia. This was 0.18 and 0.11 per 100 days respectively. It should be noted that the frequency of hypoglycaemic coma exceeded 1 per 100 days in six patients and similarly for 13 patients in respect of ketoacidosis. The mean incidence of subcutaneous infection was reported to be 0.27 per 100 days. Problems related to the technical malfunctions were observed at frequencies of up to 0.35 per 100 days. Dr. H. Kritz (Vienna) gave a report on the international registry of implantable pumps. 
